Presentations to highlight nine-year treatment outcomes and research
on the potential use of electrographic data to identify RNS System
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc., a Silicon Valley-based medical technology company,
today announced that data from two studies of the company’s RNS®
System for adults with medically refractory focal onset epilepsy will be
presented at the American Academy of Neurology (AAN) 2019 Annual Meeting
taking place May 4-10 in Philadelphia.
Results from the company’s groundbreaking Long-Term Treatment Study of
the RNS System, the largest and longest prospective neuromodulation
study, will be presented by principal investigator Dileep Nair, MD,
section head of adult epilepsy, Cleveland Clinic Neurological Institute.
In addition, new research data evaluating whether objective epilepsy
biomarkers derived from interictal electrocorticographic (ECoG) data can
be used to identify mesiotemporal lobe epilepsy (MTL) patients who
respond to treatment with the NeuroPace RNS System will be presented by
Sharanya Arcot Desai, Ph.D., senior research scientist at NeuroPace.
Nine-year Prospective Safety and Effectiveness Outcomes from the
Long-Term Treatment Trial of the RNS® System
by principal investigator Dileep Nair, M.D.
Wednesday, May 8th,
1:44 p.m. ET, S36.005
Interictal Electrographic Features Differentiate MTL Responders and
Presented by Sharanya Arcot Desai, Ph.D.
May 9th, 1:00 p.m. ET, S48.001
About the RNS® System
The RNS System is the world’s first and only closed-loop
brain-responsive neurostimulation system designed to prevent epileptic
seizures at their source. As a type of brain-computer interface, the RNS
System treats seizures by continuously monitoring brain waves,
recognizing each patient’s unique “seizure onset fingerprint,” and
automatically responding with imperceptible electrical pulses before
seizures occur. The RNS System is composed of a neurostimulator, leads
that are placed at the seizure foci, a remote monitor used by patients
to upload their data, and a RNS Tablet and Patient Data Management
System (PDMS) used by physicians. Physicians can view their patient’s
electrographic data on a secure website and program the device to
personalize therapy for each individual. Unlike anti-epileptic drugs or
resective surgery, brain-responsive neuromodulation outcomes typically
improve with time and do not cause the cognitive side effects that can
be associated with those alternatives. The RNS System is now available
at nearly all comprehensive epilepsy centers in the United States and is
widely covered by private and government insurance.
The RNS® System is an adjunctive therapy for adults with
refractory, focal onset seizures with no more than 2 epileptogenic foci.
See important safety information at www.neuropace.com/safety/.
NeuroPace is the global leader in the emerging field of brain-computer
interface technologies, which is projected to become a $1.2 billion
market by 2024. We are dedicated to developing groundbreaking technology
and advancing brain science to improve the quality of life for millions
of individuals who suffer from neurological disorders. The company’s
first product, the RNS System, is the only FDA-approved brain-responsive
neurostimulator for the treatment of focal onset refractory epilepsy. In
addition to treating epilepsy, brain-responsive neuromodulation holds
the promise of treating other brain disorders that impact quality of
life for millions of patients throughout the world.